Printer Friendly

Many Growth Opportunities Emerging in the U.S. Infectious Disease In-Vitro Diagnostics Market.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c50504) has announced the addition of Frost & Sullivan's new report: U.S. Infectious Disease Diagnostics Markets to their offering.

This research service, titled U.S. Infectious Disease Diagnostics Markets, provides comprehensive analysis of market drivers, restraints, challenges, and trends. Moreover, analysis of market share, competitive structure, revenue forecasts, and products is included. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: molecular infectious disease diagnostics, immunoassay infectious disease diagnostics, and culture infectious disease diagnostics.

Market Sectors

Expert analysts thoroughly examine the following market sectors in this research:

-- Molecular

-- Immunoassay

-- Culture

Technologies

The following technologies are covered in this research:

-- PCR

-- Automated antimicrobial susceptibility testing

-- Molecular technologies and assays

-- Immunoassays

-- Microbiology culture methods

Market Overview

The U.S. infectious disease diagnostics market will play a significant role in the dynamic IVD market. This market is segmented according to molecular, immunoassays, and culture infectious disease products. Total market revenues for base year 2005 are $3,823.1 with a CAGR of 7.7%. The most substantial growth is expected in the molecular segment. The U.S. infectious disease diagnostics market is highly competitive and saturated.

Tremendous growth opportunities exist in the U.S. infectious disease in-vitro diagnostics market. High growth areas include viral load testing, nosocomial infection screening, rapid influenza detection, and STD testing.

Rapid detection and fast turn-around time (TAT) are able to lower total overall healthcare costs. Quick TAT is especially relevant to infectious disease testing, as fast diagnosis increases treatment options and patient prognosis.

Technical superiority of molecular methods is phasing out other types or more traditional methods, such as culture based tests, which have TATs of only days and are labor intensive.

For more information visit http://www.researchandmarkets.com/reports/c50504
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 16, 2007
Words:297
Previous Article:New Superior Clinical Trial Results Drive Revenues in the U.S. Anticoagulant Market.
Next Article:Allen Iverson/LeBron James All-Star Weekend Celebration to Conclude with the LeBron James Celebrity All-Star Weekend Grand Finale.
Topics:


Related Articles
NEHA's position on emerging infectious diseases.
Preventing emerging infectious diseases: a strategy for the 21st century.
ARGENTINA APPROVES APPLIED BIOSYSTEMS' VIROSEQ KIT.
WORKSHOP ON MEASUREMENT TRACE ABILITY FOR CLINICAL LABORATORY TESTING AND IN VITRO DIAGNOSTIC (IVD) TEST SYSTEMS.
Global infectious disease policy. (Conference Summary).
Disease surveillance and the academic, clinical, and public health communities. (Synopses).
SRI International Launches Center of Excellence in Infectious Disease and Biodefense; Interdisciplinary Center to Advance Biotechnology Research for...
CytoGenix and USAMRIID to Collaborate in Developing Biodefense synDNA(TM) Vaccines.
Aethlon Medical Initiates Dengue Fever Studies with Government of India Researchers.
Exagen Diagnostics, Inc.(TM) Leads Next Phase of Genomics Revolution.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters